Pharma Report on Women Infertility – Pipeline Review, H2 2020

Source: https://www.researchbymarkets.com/report/women-infertility-pipeline-review-h2-2020-645819.html

Women Infertility – Pipeline Review, H2 2020

Summary

Women Infertility – Pipeline Review, H2 2020, provides an overview of the Women Infertility (Women’s Health) pipeline landscape.

Infertility refers to failure to conceive over the course of one full year. Women infertility is caused due to damage of fallopian tubes, ovulation disorders (polycystic ovary syndrome) and endometriosis. Symptoms include abnormal periods, weight gain, back pain, pelvic pain, and cramping. Risk factor of infertility includes smoking tobacco, using alcohol, being overweight, being exposed to toxins, certain medical conditions, including tumors and chronic illnesses. Treatment includes medications to stimulate ovulation and hormone therapies.

Report Highlights

Women Infertility – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Women Infertility (Women’s Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Women Infertility (Women’s Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 21, 16, 1, 2, 22, 8 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 3 molecules, respectively.

Women Infertility (Women’s Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women’s Health).
– The pipeline guide reviews pipeline therapeutics for Women Infertility (Women’s Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Women Infertility (Women’s Health) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Women Infertility (Women’s Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Women Infertility (Women’s Health)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Women Infertility (Women’s Health).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Women Infertility (Women’s Health) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
Adynxx Inc
AlphaMab Co Ltd
Amega Biotech
Anelleo Inc
Aprilbio Co Ltd
Aptorum Group Ltd
ARTham Therapeutics Inc
ASKA Pharmaceutical Co Ltd
Auritec Pharmaceuticals Inc
Bayer AG
Beijing Fogangren Bio-Pharm Tech Co Ltd
Beijing SL Pharmaceutical Co Ltd
Bharat Serums And Vaccines Ltd
Bol Pharma
Bopin (Shanghai) Biomedical Technology Co Ltd
Chugai Pharmaceutical Co Ltd
Context Therapeutics LLC
Daewoong Pharmaceutical Co Ltd
ElexoPharm GmbH
Enteris BioPharma Inc
Eurofarma Laboratorios SA
Evestra Inc
Evotec SE
FemmePharma Global Healthcare Inc
Ferring International Center SA
Ferring Pharmaceuticals Inc
Forendo Pharma Ltd
GeneScience Pharmaceuticals Co Ltd
Genome & Co
Glycotope GmbH
Igenomix SL
Igyxos SA
Immunitor Inc
Isifer AB
Jiangsu Hengrui Medicine Co Ltd
Kissei Pharmaceutical Co Ltd
LG Chem Ltd
Livzon Pharmaceutical Group Co Ltd
Luye Pharma Group Ltd
Mitsubishi Tanabe Pharma Corp
Myovant Sciences Ltd
Navad Life Sciences Pte Ltd
Nippon Shinyaku Co Ltd
NutriBand Inc
ObsEva SA
Oxolife SL
Pangen Biotech Inc
Park Active Molecules
Philogen SpA
Predictive Therapeutics LLC
PregLem SA
Reven Pharmaceuticals Inc
Richter Gedeon Nyrt
Shanghai Jing Ze Biotechnology Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Suzhou JiSheng Pharmaceutical Co Ltd
SYNG Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Temple Therapeutics BV
TiumBio Co Ltd
Trophogen Inc
ValiRx Plc
Viramal Ltd
Xbrane Biopharma AB


For queries regarding this report: https://www.researchbymarkets.com/sample-request/645819

Contact Us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.